SUDARSHAN share price, P/E, ROE & financials

On 6 Nov 2026, Sudarshan Pharma Industries was priced at ₹32.31, or 31.1× trailing earnings, against an industry P/E of 18.2×, and the shares are 18% below their 52-week high. Sales and net profit grew 15% and 49% a year over 3 years, with ROCE of 29% and ROE of 17%. Debt is 2.00× equity. It is a small-cap company with a market cap of ₹822 Cr, ranked 31st of 76 Chemicals companies by market cap; the shares fell 15% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year

Open: ₹32.14
Day high: ₹32.50
Day low: ₹31.02
Prev. close: ₹32.13
Volume: 23.2K

Health check

2 good · 1 fair · 3 to check

ReturnsIn line
−14.8% over a year, better than 3 of 7 peers.
Price tagPricier
P/E 31.1 vs industry 18.2.
GrowthStrong
Sales +15.1%, profit +49.0% a year over 3 years.
ProfitabilityStrong
ROCE 28.8% vs peer median 10.6%.
Balance sheetStretched
Debt 2.00× equity, interest covered 2.3×, Piotroski 2 of 9.
Red flags3 to check
Debt is 2.00× equity.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Chemicals

75 listed peers. Screen the industry

Small cap

₹822 Cr, #31 of 76 in its industry by size.

Moves with the market

Beta 0.88 vs the NIFTY 50: tracks the market closely.

Key metrics

Last 12 months to Jun 2026: sales ₹780 Cr · profit ₹29 Cr

Market cap: ₹822 Cr; Small cap
P/E: 31.1; Industry 18.2
Price to book: 4.31; Peers 2.62
Dividend yield: 0.00%
ROE: 17.2%; Peers 11.7%
ROCE: 28.8%; Peers 10.6%
Debt to equity: 2.00; Debt ₹392 Cr
EPS (TTM): ₹1.04; Face value ₹1
OPM (TTM): 8.2%; Net margin 3.7%
Sales growth: +20.1%; Latest quarter vs a year ago
Profit growth: +45.0%; Latest quarter vs a year ago
Price to sales: 1.05; EV/EBITDA 18.4

Strengths

Return on capital employed of 28.8%.
Quarterly profit up 45.0% on a year ago.
Quarterly sales up 20.1% on a year ago.

Risks to check

Debt is 2.00× equity.
P/E of 31.1 against an industry P/E of 18.2.
Interest coverage of only 2.2×.

Derived automatically from reported figures. Not a recommendation.

About Sudarshan Pharma Industries

Sudarshan Pharma Industries Limited manufactures and sells specialty chemicals and intermediates for pharma, paints, food, adhesives, and various other industries in India and United States. The company also focuses on manufactures active pharmaceuticals ingredients and vitamins manufacturing. In addition, it offers fine chemicals, solvents, agro chemicals, finish lubricants, inks, food colors, leather chemicals, oil field chemicals, lubricant…

Headquarters: Mumbai
Employees: 64
Sector: Basic Materials
ISIN: INE00TV01023
Website: sudarshanpharma.com

Price range

52 weeks

₹31.01₹39.30

Today

₹31.02₹32.50

Avg volume (3M): 1.3 L
1-year return: minus 14.8%
From 52-week high: minus 17.8%

Peers · Chemicals

Capital-heavy industry columns

Compare with peers Screen the whole industry

Company
NAVINFLUORNavin Fluorine International	9,010.00	plus 1.87%	46,250	50.8	42.7	18.7%	34.3%	0.28	16.5%	plus 46.1%
DEEPAKNTRDeepak Nitrite	1,533.60	minus 0.67%	20,917	19.7	22.3	10.8%	18.0%	0.27	−0.5%	minus 11.9%
TATACHEMTata Chemicals	607.45	minus 1.36%	15,475	–	12.4	−3.0%	12.2%	0.36	−4.8%	minus 31.0%
DEEPAKFERTDeepak Fertilisers & Petrochemicals Corp.	1,155.30	minus 0.69%	14,599	14.8	11.5	11.2%	17.6%	0.76	2.6%	minus 22.7%
RPELRaghav Productivity Enhancers	1,780.80	plus 0.95%	8,178	116.0	107.1	–	29.9%	0.02	23.5%	plus 95.4%
GNFCGujarat Narmada Valley Fertilizers and Chemicals	451.80	minus 1.87%	6,639	6.3	5.4	10.4%	14.8%	0.01	−8.8%	minus 7.2%
ACIArchean Chemical Industries	416.40	minus 1.95%	5,141	51.3	23.2	7.7%	20.0%	0.28	−9.2%	minus 34.6%
SUDARSHANSudarshan Pharma Industries	32.31	plus 0.56%	822	31.1	21.6	28.8%	8.9%	2.00	15.1%	minus 14.8%
Median of 7 peers	–	−0.69%	14,599	35.2	22.3	10.6%	18.0%	0.28	−0.5%	−11.9%

Quarterly results

Consolidated, ₹ crore

SalesSelect a row below to chart it

Mar 25	Jun 25	Dec 25	Mar 26	Jun 26
162	145	168	221	174
–	–	–	+36.7%	+20.1%
146	134	157	201	159
15.9	11	10.9	20.2	15.9
9.9%	7.6%	6.5%	9.1%	9.1%
0.8	1.2	1.5	4.1	1.2
4.4	6	6.3	7.5	8.2
0.8	0.9	0.9	1.1	1.4
−1.6	–	–	–	–
9.9	5.4	5.2	15.7	7.5
25.1%	26.8%	20.2%	27.5%	25.3%
7.4	4	4.4	10.7	5.9
–	–	–	+44.7%	+45.0%

Sep 25 not reported by the data source.

Profit & loss

Yearly, ₹ crore

Sales CAGR 3Y: +15.1%
Profit CAGR 3Y: +49.0%
ROE: 17.2%

Net profitSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
461	464	505	703
–	+0.5%	+9.0%	+39.2%
446	441	469	652
15.3	22.8	36.4	51.3
3.3%	4.9%	7.2%	7.3%
−0.1	1.5	3.1	4.4
4.6	7.9	14	22.9
0.9	1.2	2.8	3.8
−0.2	–	−2.7	1.5
9.5	15.2	20	30.5
25.9%	24.8%	25.2%	23.5%
7	11.5	14.9	23.3
–	+62.8%	+30.3%	+56.1%

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore

Total assetsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
24.1	24.1	24.1	24.1
76.9	88.9	108	131
34.1	107	175	285
97.4	66.9	99.9	202
232	287	406	642
19.1	29.3	53.4	93.4
0.1	1.9	22.5	16
0	0	0	0
11.7	0.1	0.6	1.1
202	255	330	531
232	287	406	642

Cash flow

Yearly, ₹ crore

Cash from operationsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
−28.8	7.8	−32.3	−2.3
−25.7	−7.2	−20.7	−77.7
65.9	−12.1	53.3	79.2
11.5	−11.6	0.4	−0.8
−13.8	−3.8	−21.2	−69.1
−42.6	4	−53.6	−71.4
–	−0.7	–	–

Shareholding pattern

Source: NSE filings

NSE hasn’t returned a shareholding pattern for this company.

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you